01.09.2016 • News

China Petchems Firms Plan CO2 Benchmarking

(c) Kodda/Shutterstock
(c) Kodda/Shutterstock

Chinese refiners and petrochemical producers plan to set up a system for benchmarking their carbon dioxide (CO2) emissions as the first step toward setting up an emissions market for the sector. The China Petroleum and Chemical Industry Federation (CPCIF), a lobbying group for the country’s oil industry, said in its China Chemical Industry News newsletter it will make a proposal by September on how to set benchmarks for the CO2 produced while manufacturing products ranging from diesel fuel to benzene.

According to CPCIF, the benchmarks will be used to set CO2 emissions caps for nearly 2,400 companies in the sector under the national carbon market slated to start next year. This will help create reduction targets for the large petrochemical and chemical plants said to account for up to 70% of the sector's CO2 emissions. China is the world's second-largest oil consumer behind the US. Altogether 8,000 companies in eight industries are planned to be included in the national carbon trading scheme, including players in the power, steel, cement and transportation sectors.

Petrochemical and other chemical producers participating in China's domestic carbon market will account for one-third of all companies participating nationally, Li Yongliang, a CPCIF official, told China Chemical Industry News.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read